About this trial
Primary ciliary dyskinesia (PCD) is a rare disease, caused by impairment of the motile cilia. Patients present with chronic upper and lower respiratory tract infections. The therapy is mainly supportive and based on that of cystic fibrosis. Chest physiotherapy is one of the cornerstones of the therapy, however the influence of chest physiotherapy on lung function (short term and long term) is not clear. For interpretation of longitudinal lung function data it is important to examine the short time effect of chest physiotherapy. We hypothesize that a session of chest physiotherapy improves lung function and that thus lung function tests must be performed in a standardized way.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Primary ciliary dyskinesia
able to perform spirometry and MBW (>6 years)
Disqualifiers
acute exacerbation
Trial design
Single group
Treatments tested in this trial
Chest physiotherapy
Procedure/Surgery20 minutes of chest physiotherapy by physiotherapist
Treatment groups
Trial outcomes
Primary outcomes
Difference in FEV1 before and after treatment
Lung function will be performed before a session of chest physiotherapy, and repeated 30 minutes after a chest physiotherapy session of 20 minutes with airway clearance techniques and use of PEP mask
Secondary outcomes
Difference in LCI before and after chest physiotherapy
Multiple Breath Washout (MBW) will be performed before and 30 min after a session of chest physiotherapy. The difference in LCI (lung clearance index) will be used as secondary outcome.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.